Physician

Kalust Ucar, M.D.

According to 2025 Medicare claims, Kalust Ucar, M.D. (NPI: 1710912175) practices hematology/oncology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is CITY OF HOPE MEDICAL FOUNDATION (NPI: 1871886366; TIN: 274803222) and primary practice location at 91204-2850.

Ucar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,261 traditional Medicare patients, billed 496,475 HCPCS/CPT codes, and received $6,511,103 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,774 prescription claims across 336 beneficiaries totaling $7,633,454 in drug costs, led by Tagrisso (Osimertinib Mesylate). DME data shows 215 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $2,376,618 to $6,511,103. Similarly, Part D prescription costs have risen steadily, from $1,107,695 to $7,633,454. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,006	223,735	$2,376,618
2016	1,036	342,062	$3,563,441
2017	1,057	414,293	$3,544,728
2018	1,143	417,033	$4,693,073
2019	1,205	484,663	$6,127,877
2020	1,190	472,785	$8,276,705
2021	1,165	458,983	$8,459,059
2022	1,180	414,956	$5,086,658
2023	1,172	493,939	$5,859,952
2024	1,261	496,475	$6,511,103

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	266	2,058	$1,107,695
2016	271	2,155	$1,476,554
2017	282	2,110	$1,615,884
2018	260	2,079	$2,399,531
2019	208	1,602	$1,807,278
2020	185	1,175	$1,528,666
2021	220	1,250	$2,859,539
2022	274	2,194	$5,150,742
2023	303	2,035	$4,224,964
2024	336	2,774	$7,633,454

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	56	157	$66,937
2016	79	281	$78,136
2017	104	228	$45,582
2018	54	120	$13,869
2019	43	87	$9,760
2020	36	114	$10,090
2021	38	139	$12,810
2022	77	177	$12,341
2023	25	108	$21,246
2024	49	215	$6,534

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	172	172	$186
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	241	385	$156
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	800	1,569	$102
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	319	434	$14
96372	Injection of drug or substance under skin or into muscle	218	845	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tagrisso	Osimertinib Mesylate	60	1,800	$974,323
Xtandi	Enzalutamide	56	1,680	$744,857
Ibrance	Palbociclib	42	1,169	$642,097
Jakafi	Ruxolitinib Phosphate	38	1,140	$618,274
Cabometyx	Cabozantinib S-Malate	20	600	$481,224

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	16	65	$2,686
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	22	80	$1,449
J8999	Prescription drug, oral, chemotherapeutic, nos	N	11	20	$920
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	13	$761
J8700	Temozolomide, oral, 5 mg	N	N/R	17	$467

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Kalust Ucar, M.D.?

Tedicare shows public-source Medicare data for Kalust Ucar, M.D. (NPI 1710912175), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kalust Ucar, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kalust Ucar, M.D.?

Kalust Ucar, M.D. is linked to CITY OF HOPE MEDICAL FOUNDATION (billing NPI 1871886366) in the available physician profile data.

Does Kalust Ucar, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.